Press Release|

SHL partner in connected pen injectors, Innovation Zed Ltd., forges new commercial partnership with A. Menarini Diagnostics

Insulcheck 200211 W1200On January 28, Innovation Zed Ltd., a developer of connected health solutions, entered into a commercial partnership with diagnostics and preventive medicine company A. Menarini Diagnostics to market the insulin pen “InsulCheck Connect” add-on device.

InsulCheck Connect is an innovative device that is compatible with various conventional insulin pens1. A connected device solution that serves as a secondary aid in the management of diabetes, InsulCheck Connect can record the time and frequency of injection and send this data to the patient’s mobile device. SHL is the official partner of Innovation Zed in the design and development of connected solutions for pen injectors.

“As Innovation Zed’s partner in connected pen injectors, we see this new commercial partnership as part of every stakeholder’s shared commitment in creating enhanced services in the drug delivery market, eventually benefiting the patients, who are the end users,” Christian Keller, SHL’s Director of Engineering Solutions said.

Meanwhile, Dean Minnock, Director of Business Development at Innovation Zed, affirms the promise of this commercial agreement, citing A. Menarini Diagnostics’ years of expertise in providing healthcare products and services, as well as its strong commitment to developing fully integrated products.

With the increasing importance of digital technologies and its advantages in improving the future of healthcare, SHL is actively collaborating with digital healthcare companies to further develop and establish connected devices and remote care services that will help improve disease management .

A full copy of the official press release can be found here.

1Please refer to “InsulCheck Connect” website for a list of compatible insulin pen injectors

About SHL

SHL Group is a world-leading solutions provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit

Media contact:


Related News